Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 8
2004 7
2005 4
2006 10
2007 3
2008 16
2009 25
2010 33
2011 31
2012 42
2013 35
2014 42
2015 41
2016 53
2017 34
2018 43
2019 48
2020 50
2021 61
2022 48
2023 34
2024 23

Text availability

Article attribute

Article type

Publication date

Search Results

581 results

Results by year

Filters applied: . Clear all
Page 1
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. N Engl J Med. 2019 Mar 28;380(13):1235-1246. doi: 10.1056/NEJMoa1815671. Epub 2019 Feb 14. N Engl J Med. 2019. PMID: 30763142 Clinical Trial.
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.
Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, Arslan C, Mehra N, Parnis F, Brown E, Schlürmann F, Joung JY, Sugimoto M, Sartor O, Liu YZ, Poehlein C, Barker L, Del Rosario PM, Armstrong AJ. Saad F, et al. Among authors: oya m. Lancet Oncol. 2023 Oct;24(10):1094-1108. doi: 10.1016/S1470-2045(23)00382-0. Epub 2023 Sep 12. Lancet Oncol. 2023. PMID: 37714168 Clinical Trial.
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. N Engl J Med. 2020 Sep 10;383(11):1040-1049. doi: 10.1056/NEJMoa2001342. N Engl J Med. 2020. PMID: 32905676 Clinical Trial.
Editorial Comment.
Yazawa S, Oya M, Nakajima Y. Yazawa S, et al. Among authors: oya m. J Urol. 2019 Nov;202(5):1000. doi: 10.1097/01.JU.0000578560.21169.3f. Epub 2019 Oct 9. J Urol. 2019. PMID: 31339421 No abstract available.
Is inflammation related to any diseases?
Oya M. Oya M. Int J Urol. 2013 Feb;20(2):135. doi: 10.1111/iju.12068. Int J Urol. 2013. PMID: 23368641 No abstract available.
Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study.
Grünwald V, Powles T, Kopyltsov E, Kozlov V, Alonso-Gordoa T, Eto M, Hutson T, Motzer R, Winquist E, Maroto P, Keam B, Procopio G, Wong S, Melichar B, Rolland F, Oya M, Rodriguez-Lopez K, Saito K, McKenzie J, Porta C. Grünwald V, et al. Among authors: oya m. Eur Urol Oncol. 2023 Aug;6(4):437-446. doi: 10.1016/j.euo.2023.01.010. Epub 2023 Jan 29. Eur Urol Oncol. 2023. PMID: 36720658 Free PMC article. Clinical Trial.
MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
Yasumizu Y, Rajabi H, Jin C, Hata T, Pitroda S, Long MD, Hagiwara M, Li W, Hu Q, Liu S, Yamashita N, Fushimi A, Kui L, Samur M, Yamamoto M, Zhang Y, Zhang N, Hong D, Maeda T, Kosaka T, Wong KK, Oya M, Kufe D. Yasumizu Y, et al. Among authors: oya m. Nat Commun. 2020 Jan 17;11(1):338. doi: 10.1038/s41467-019-14219-6. Nat Commun. 2020. PMID: 31953400 Free PMC article.
Characterization of Aldosterone-producing Cell Cluster (APCC) at Single-cell Resolution.
Iwahashi N, Umakoshi H, Seki T, Gomez-Sanchez CE, Mukai K, Suematsu M, Umezawa Y, Oya M, Kosaka T, Seki M, Suzuki Y, Horiuchi Y, Ogawa Y, Nishimoto K. Iwahashi N, et al. Among authors: oya m. J Clin Endocrinol Metab. 2022 Aug 18;107(9):2439-2448. doi: 10.1210/clinem/dgac394. J Clin Endocrinol Metab. 2022. PMID: 35796577 Free PMC article.
Three-dimensional single-cell imaging for the analysis of RNA and protein expression in intact tumour biopsies.
Tanaka N, Kanatani S, Kaczynska D, Fukumoto K, Louhivuori L, Mizutani T, Kopper O, Kronqvist P, Robertson S, Lindh C, Kis L, Pronk R, Niwa N, Matsumoto K, Oya M, Miyakawa A, Falk A, Hartman J, Sahlgren C, Clevers H, Uhlén P. Tanaka N, et al. Among authors: oya m. Nat Biomed Eng. 2020 Sep;4(9):875-888. doi: 10.1038/s41551-020-0576-z. Epub 2020 Jun 29. Nat Biomed Eng. 2020. PMID: 32601394
581 results